Related references
Note: Only part of the references are listed.Hypoxia inducible factor 1α gene (HIF-1α) splice variants: potential prognostic biomarkers in breast cancer
Jean-Philippe Dales et al.
BMC MEDICINE (2010)
Inhibiting the Hypoxia Response for Cancer Therapy: The New Kid on the Block
Mei Yee Koh et al.
CLINICAL CANCER RESEARCH (2009)
Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia
Ilse J. Hoogsteen et al.
EUROPEAN JOURNAL OF CANCER (2009)
Role of Hypoxia in the Hallmarks of Human Cancer
Kai Ruan et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
Detection and specific targeting of hypoxic regions within solid tumors: Current preclinical and clinical strategies
M. Bache et al.
CURRENT MEDICINAL CHEMISTRY (2008)
The effects of knockdown of wild-type survivin, survivin-2B or survivin-Δ3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions
M. Kappler et al.
CANCER GENE THERAPY (2007)
Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells
Adrian Staab et al.
BMC CANCER (2007)
Hypoxic radiosensitization: Adored and ignored
Jens Overgaard
JOURNAL OF CLINICAL ONCOLOGY (2007)
Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting
Mark W. Dewhirst
CANCER RESEARCH (2007)
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance
Donal J. Brennan et al.
CLINICAL CANCER RESEARCH (2006)
Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine:: A substudy of Trans-Tasman Radiation Oncology Group study 98.02
D Rischin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial
J Overgaard et al.
LANCET ONCOLOGY (2005)
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study
M Nordsmark et al.
RADIOTHERAPY AND ONCOLOGY (2005)
Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1
KJ Williams et al.
RADIOTHERAPY AND ONCOLOGY (2005)
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
AL Kung et al.
CANCER CELL (2004)
Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma
R Bos et al.
CANCER (2003)
Share Paper
